BioSpace News Archive

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2021 financial results will be released on Thursday, March 3, 2022 before the U.S. financial markets open.

Outlook Therapeutics, Inc. announced that Lawrence Lee, MD, MBBS, FRANZCO, FRACS, Associate Professor of Ophthalmology at the University of Queensland and Director of the City Eye Center in Brisbane, Australia, will present pivotal safety and efficacy data from Outlook Therapeutics’ Phase 3 NORSE TWO registration trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab, for use in wet AMD.

HiberCell has initiated a Phase 1a/b clinical trial of HC-7366, a first-in-class selective, orally bioavailable modulator of General Control Nonderepressible 2 (GNC2) for the treatment of patients with advanced solid tumors.

Pasithea Therapeutics Corp. announced that its wholly owned subsidiary, Pasithea Clinics, has expanded its treatment offerings and is planning to open three new clinics in London to treat patients suffering from mental health issues.

Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in the following conferences in March.

Alimera Sciences, Inc. today announced financial results for the fourth quarter and full year 2021.

Reports full year 2021 revenue of $85.4 million, above pre-announced preliminary range Reiterates 2022 revenue outlook

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period for the supplemental New Drug Application (sNDA) for IMCIVREE.

Genus plc is pleased to announce that PIC has entered into definitive agreements with Olymel LP, a leader in the Canadian agrifood industry, for provision of genetic products and services in connection with the Olymel’s AlphaGene porcine genetic improvement program.

HAVN Life Sciences Inc. is pleased to announce it has successfully secured a purchase order for naturally derived psilocybin from their Canadian supply partner, Revive Therapeutics Ltd.